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Table 1
Antibiotic failure in MRSA infections
Antibiotic number of
patents
receiving
the
antibiotic
number of
patients
who failed
the
antibiotic
percentage
of failure
(%)
vancomycin 164 15 9.1
daptomycin 21 3 1.42
tigecycline 13 4 30.7
telavancin 1 0 0
trimethoprim-sulfamethoxazole 15 11 73.3
linezolid 11 2 18.1
doxycycline 2 1 50
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Background: Uncontrolled usage of antibiotics has caused the
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attern of antibiotic usage for treatment of methicillin resis-
ant Staphylococcus aureus infections and their outcomes at a
ertiary care hospital in Springﬁeld, Illinois
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SIU school of medicine, Springﬁeld, il, USA
Southern Illinois University School of Medicine, Springﬁeld, IL, USA
Southern Illinois University School of Pharmacy, Edwardsville, IL, USA
Background: Despite the availability of multiple new antibi-
tics for the treatment of methicillin resistant staphylococcus
ureus (MRSA), vancomycin has remained an important anti-
taphylococcal antibiotic. Even after 50 years since it was ﬁrst
ntroduced, it still remains the drug of choice for treatment of com-
licated MRSA infections during hospitalization. If vancomycin is
ptimally dosed, clinical failure rates with vancomycin are fairly
ow. In this study, we analyzed the pattern of antibiotic usage for
reatment of MRSA infections and their outcomes in a tertiary care
ospital at Springﬁeld, Illinois.
Methods: This study is a retrospective review of 304 charts
f patients with MRSA infections seen between January 2009 and
ecember 2009.We analyzed the type of infection, choice of antibi-
tic and their outcome in these patients. Tables 1 and 2 summarize
he results. For the purpose of this study,we deﬁned treatment fail-
re as clinically worsening while on treatment requiring change to
nother anti-staphylococcal antibiotic for the same infection, iso-
able 2
ype of infection and speciﬁc antibiotic failure
Skin and
soft tissue
infection
bone and
joint
infection
vancomycin 13 17
trimethoprim-sulfamethoxazole 3 41
daptomycin - 1
clindamycin 3 1
levoﬂoxacin 6 1
linezolid 1 -
tigecycline - 4
doxycycline - 1
telavancin - -
total 26 29Figure 1. Antibiotic (all) failure in the type of infection.
lation of MRSA from the same or another site while on presumed
effective treatment.
Results: Of the 304 charts screened, 49 charts had incomplete
information. Of the remaining 255 patients included in the study,
the following tables andﬁgures summarize the antibiotic usage and
failure.
Figure 1.
Conclusion: Vancomycin was used in the majority of serious
MRSA infections and the antibiotic failure with vancomycin was
lower thanmost other antibiotics used except for daptomycin. This
study is unique since it assesses the usage of different anti staphy-
lococcal drugs and their failure rates. The data is afﬁrmative for
vancomycin as the drug of choice for complicated MRSA infections
despite reported increase in failure rates.
http://dx.doi.org/10.1016/j.ijid.2012.05.629
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Bacteriophages–alternativeapproach to treat infections caused
by bacterial pathogens
M. Kutateladze ∗, R. Adamia
Eliava Institute of bacteriophages, Tbilisi, Georgiarapid development of multidrug resistant bacterial pathogens all
over the world. The challenges in the treatment of infectious
diseases are leading the search for alternative remedies. In the
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re-antibiotic era of the early 20th century, phage therapy was
ecoming a powerful weapon against infectious diseases of bac-
erial etiology. Unfortunately, phage treatment and research was
argely forgotten in theWesternworldas antibioticsbecamewidely
vailable. Nowadays, the rapid propagation of multi-drug resistant
acterial strains is leading to renewed interest in phage therapy.
Methods: In contrast to its decline in the West, phage ther-
py remained a standard part of the healthcare systems in Eastern
urope and the USSR during the second half of the 20th cen-
ury. Phage preparations were used for diagnostic, therapeutic and
rophylactic purposes to combat various bacterial infections. The
liava Institute of Bacteriophages,Microbiology and Virology (Tbil-
si, Georgia) has been focused on the study of bacteriophages for
any years, particularly the isolation and selection of phages active
gainst various bacterial pathogens, including the most dangerous
acteria.
Results: Bacteriophages have a number of advantages in com-
arison to antibiotics. They are safe, very speciﬁc and do not affect
ormal microﬂora. Today, many patients from various parts of the
orld express their willingness to take phage treatment against
ifferent infections, including those that are caused by antibiotic-
esistant bacterial pathogens. Phage preparations are used to treat
ocal infections (i.e. throat, eye, and ear), infectious wounds and
urns, urinary, respiratory and intestinal tracts infections
Conclusion: Phage therapy as an alternative approach for treat-
ent of infections has reemerged as an evident and promising
emedy. Currently, the Eliava Institute is developing new phage-
ased products and technological schemes for phage production.
ttp://dx.doi.org/10.1016/j.ijid.2012.05.630
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Background: Inappropriate empiric antimicrobial therapy
ould lead to unfavorablemortality rate in co-morbid patients. This
tudy aimed to assess the impact of inappropriate antimicrobial on
he mortality of septic patients with bacteremia in a Thai tertiary
ospital.
Methods: A retrospective study was employed in bacteremic
atients with sepsis, severe sepsis, or septic shocks during 2009
t Siriraj Hospital. Demographic data, antimicrobial use and the
rst-dose timing, type of bacteria isolated from blood and their
usceptibilities, 28-day and overall mortality rate were collected
nd analyzed. Inappropriate antimicrobial was deﬁned by the non-
usceptibility of the isolated bacteria to the ﬁrst-dose empiric
ntimicrobial or at 24 hours after the ﬁrst dose.
Results: There were 229 patients with mean age (SD) of 63.5
17.2) years. The mean (SD) APACHE II score was 24.7 (6.8), of
hich 99.1% had at least one co-morbidity. The ﬁrst-dose and 24-
our inappropriate antimicrobial was found in 29.7% and 25.3%,
espectively. The28-day andoverallmortality between inappropri-
te and appropriate antimicrobial were 67.6% vs 60.2% (p=0.301)fectious Diseases 16S (2012) e317–e473
and 75.0% vs 68.3% (p=0.345), subsequently. In patients with sep-
tic shock, inappropriate antimicrobial use signiﬁcantly had higher
28-day mortality than the appropriate antimicrobial use (61.6%
vs 41.9%; p=0.017). Inappropriate ﬁrst-dose antimicrobial was
noticed in64.7%and62.2%among thedrug-resistantGram-positive
and Gram-negative bacteremia. The golden period of appropriate
antimicrobial was less than 3 hours after diagnosis (OR 1.08-1.92,
95% CI 1.08-3.42). From multivariate analysis, inappropriate ﬁrst-
dose antimicrobial (OR 2.52), the ﬁrst-dose timing over 3 hours
(OR 1.8), APACHE II score > 25 (OR 1.66), serum albumin < 3.2 g/dl
(OR 2.52), and septic shock (OR 1.93) were associated with over-
all mortality. Factors related to inappropriate antimicrobial were
nosocomial infections (OR 3.31), leukopenia (OR 2.45) and drug-
resistant gram-positive (OR 6.03) and gram-negative organisms
(OR 10.76).
Conclusion: Inappropriate antimicrobial was discovered in
29.7% of the bacteremic patients with 6.7% excess mortality and
signiﬁcantly higher in the patients with septic shock (19.7%).
Nosocomial infections, leukopenia and drug-resistant organisms
were factors of inappropriate antimicrobial. Appropriate antimi-
crobial over 3 hours increased mortality rate to 13.5%. Hence, the
importance of early appropriate empirical antimicrobial should be
ratiﬁed.
http://dx.doi.org/10.1016/j.ijid.2012.05.631
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Background: Antimicrobial resistance has been increasing in
hospital and community-acquired pathogens; few new antimi-
crobials are on the horizon. Stewardship programs (SP) optimize
antimicrobial use and have the potential to prolong efﬁcacy of
current agents as well as improve quality and cost-effectiveness.
However, case review and correlation of diagnoses, antimicrobial
dosing, allergies, and microbiologic data, and monitoring outcome
are time-consuming and labor intensive.
Methods: Bryn Mawr Hospital is a 335-bed community teach-
inghospital that converted to an electronicmedical record (EMR) in
July 2007 and instituted computerized order entry (CPOE) in June
2010. In September 2010, an antimicrobial SP was developed with
one infectious diseases physician and one pharmacist. Selected
broad spectrum and/or costly antibiotic usages are reviewed daily.
The EMR allowed rapid evaluation of antibiotic use from a cen-
tral location. Actions were based on formulary restriction of agents
and institutional practice guidelines. Data was collected on cases
reviewed, interventions necessary, days of therapy (DOT) per 1000
patient-days, cost reduction, and impact on institutional antibi-
ograms.
Results: Initially, about 40% of interventions resulted in dis-
continuation of targeted antibiotic, 30% of cases were deferred
